Pfizer Inc
PFE- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000078003
No open-market purchases or sales by Pfizer Inc insiders were filed in the last 90 days; 2,858 institutions reported holding it in 13F filings for Q2 2026, worth $91.9B in total; Fairfax Financial is the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:03 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 3, 2026 | Feb 4, 2025 | Jan 30, 2024 | Jan 31, 2023 | Feb 8, 2022 |
| Revenue | $62.6B | $63.6B | $58.5B | $100.3B | $81.3B |
| Cost of revenue | $16.1B | $17.9B | $25.0B | $34.3B | $30.8B |
| Research and development | $10.4B | $10.8B | $10.7B | $11.4B | $13.8B |
| Selling, general and administrative | $13.8B | $14.7B | $14.8B | $13.7B | $12.7B |
| Interest expense | $2.67B | $3.09B | $2.21B | $1.24B | $1.29B |
| Income tax | -$266.0M | -$28.0M | -$1.11B | $3.33B | $1.85B |
| Net income | $7.77B | $8.03B | $2.12B | $31.4B | $22.0B |
| EPS, basic | $1.37 | $1.42 | $0.38 | $5.59 | $3.92 |
| EPS, diluted | $1.36 | $1.41 | $0.37 | $5.47 | $3.85 |
| Weighted shares, basic | 5.68B | 5.66B | 5.64B | 5.61B | 5.60B |
| Weighted shares, diluted | 5.71B | 5.70B | 5.71B | 5.73B | 5.71B |
| Margins and growth | |||||
| Net margin | 12.4% | 12.6% | 3.6% | 31.3% | 27.0% |
| Revenue growth, year over year | −1.6% | +8.8% | −41.7% | +23.4% | +94.0% |
| Net income growth, year over year | −3.2% | +279.0% | −93.2% | +42.7% | +128.6% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 3, 2026 | Feb 4, 2025 | Jan 30, 2024 | Jan 31, 2023 | Feb 8, 2022 |
| Cash and equivalents | $1.14B | $1.04B | $2.85B | $416.0M | $1.94B |
| Accounts receivable | $11.9B | $11.5B | $11.2B | $11.0B | $11.5B |
| Inventory | $10.7B | $10.9B | $10.2B | $8.98B | $9.06B |
| Total current assets | $42.9B | $50.4B | $43.3B | $51.3B | $59.7B |
| Property, plant and equipment | $19.3B | $18.4B | $18.9B | $16.3B | $14.9B |
| Goodwill | $71.3B | $68.5B | $67.8B | $51.4B | $49.2B |
| Intangible assets | $53.7B | $55.4B | $64.9B | $43.4B | $25.1B |
| Total assets | $208.2B | $213.4B | $226.5B | $197.2B | $181.5B |
| Accounts payable | $5.24B | $5.63B | $6.71B | $6.81B | $5.58B |
| Short-term debt | $3.15B | $6.95B | $10.3B | $2.94B | $2.24B |
| Total current liabilities | $37.0B | $43.0B | $47.8B | $42.1B | $42.7B |
| Long-term debt | $61.6B | $57.4B | $61.5B | $32.9B | $36.2B |
| Total liabilities | $121.4B | $124.9B | $137.2B | $101.3B | $104.0B |
| Shareholders' equity | $86.8B | $88.5B | $89.3B | $95.9B | $77.5B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 3, 2026 | Feb 4, 2025 | Jan 30, 2024 | Jan 31, 2023 | Feb 8, 2022 |
| Operating cash flow | $11.7B | $12.7B | $8.70B | $29.3B | $32.6B |
| Capital expenditures | $2.63B | $2.91B | $3.91B | $3.24B | $2.71B |
| Free cash flow | $9.07B | $9.84B | $4.79B | $26.0B | $29.9B |
| Depreciation and amortization | $6.59B | $7.01B | $6.29B | $5.06B | $5.19B |
| Stock-based compensation | $799.0M | $877.0M | $525.0M | $872.0M | $1.18B |
| Share buybacks | – | $0 | $0 | $2.00B | $0 |
| Investing cash flow | -$1.35B | $2.65B | -$32.3B | -$15.8B | -$22.5B |
| Financing cash flow | -$10.3B | -$17.1B | $26.1B | -$14.8B | -$9.82B |
| Net change in cash | $91.0M | -$1.81B | $2.45B | -$1.51B | $159.0M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 1.3% | 1.4% | 0.9% | 0.9% | 1.5% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.